Qualification of Drivers; Exemption Applications; Implantable Cardioverter Defibrillator (ICD), 2291-2292 [2018-00560]
Download as PDF
Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices
exemption with respect to a person
operating under the exemption.
ACTION:
Based upon its evaluation of the 25
exemption applications, FMCSA
exempts the following drivers from the
vision requirement, 49 CFR
391.41(b)(10), subject to the
requirements cited above:
Paul A. Bartels (WI)
Harold J. Bartley, Jr. (KY)
Charles C. Berns (IA)
Eric L. Boyle, Jr. (MD)
Jeremiah E. Casey (MO)
Leonard M. Cassieri (CA)
Randy J. Conrad (IA)
Jimmie E. Curtis (NM)
Daniel E. Delano (VA)
Jonathan P. Edwards (PA)
James A. Green (IL)
Richard Healy (MD)
Tommy G. Hillis (TX)
Richard A. Honstad (MN)
Stephen M. Lovell (TX)
Thomas P. Maio (ME)
Carlos Marquez (WI)
Jason L. McBride (MI)
Dennis M. Olson (WI)
Kameron W. Quinalty (AR)
Daniel C. Sagert (WI)
Robert D. Steele (WA)
Richard C. Strassburg (NY)
Jeremy E. Studebaker (IN)
Daniel D. Woodworth (LA)
In accordance with 49 U.S.C. 31136(e)
and 31315, each exemption will be valid
for two years from the effective date
unless revoked earlier by FMCSA. The
exemption will be revoked if the
following occurs: (1) The person fails to
comply with the terms and conditions
of the exemption; (2) the exemption has
resulted in a lower level of safety than
was maintained prior to being granted;
or (3) continuation of the exemption
would not be consistent with the goals
and objectives of 49 U.S.C. 31136 and
31315.
Issued on: January 5, 2018.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2018–00599 Filed 1–12–18; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
daltland on DSKBBV9HB2PROD with NOTICES
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2017–0116]
Qualification of Drivers; Exemption
Applications; Implantable Cardioverter
Defibrillator (ICD)
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
VerDate Sep<11>2014
22:48 Jan 12, 2018
Jkt 244001
FMCSA announces its
decision to deny applications from two
individuals treated with Implantable
Cardioverter Defibrillators (ICDs) who
requested an exemption from the
Federal Motor Carrier Safety
Regulations (FMCSRs) prohibiting
operation of a commercial motor vehicle
(CMV) in interstate commerce by
persons with a current clinical diagnosis
of myocardial infarction, angina
pectoris, coronary insufficiency,
thrombosis, or any other cardiovascular
disease of a variety known to be
accompanied by syncope, dyspnea,
collapse, or congestive heart failure.
FOR FURTHER INFORMATION CONTACT: Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are from 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Services, telephone (202) 366–9826.
SUPPLEMENTARY INFORMATION:
SUMMARY:
VII. Conclusion
AGENCY:
Notice of denials.
I. Electronic Access
You may see all the comments online
through the Federal Document
Management System (FDMS) at: https://
www.regulations.gov.
Docket: For access to the docket to
read background documents or
comments, go to https://
www.regulations.gov and/or Room
W12–140 on the ground level of the
West Building, 1200 New Jersey Avenue
SE, Washington, DC, between 9 a.m. and
5 p.m., ET, Monday through Friday,
except Federal holidays.
Privacy Act: In accordance with 5
U.S.C. 553(c), DOT solicits comments
from the public to better inform its
rulemaking process. DOT posts these
comments, without edit, including any
personal information the commenter
provides, to https://www.regulations.gov,
as described in the system of records
notice (DOT/ALL–14 FDMS), which can
be reviewed at https://www.dot.gov/
privacy.
II. Background
On May 4, 2017, FMCSA published a
FR notice (82 FR 20961) announcing
receipt of applications from two
individuals treated with ICDs and
requested comments from the public.
These two individuals requested an
exemption from 49 CFR 391.41(b)(4)
which prohibits operation of a CMV in
interstate commerce by persons with a
PO 00000
Frm 00161
Fmt 4703
Sfmt 4703
2291
current clinical diagnosis of myocardial
infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other
cardiovascular disease of a variety
known to be accompanied by syncope,
dyspnea, collapse, or congestive heart
failure. The public comment period
closed on June 5, 2017, and two
comments were received.
FMCSA has evaluated the eligibility
of these applicants and concluded that
granting these exemptions would not
provide a level of safety that would be
equivalent to or greater than, the level
of safety that would be obtained by
complying with the regulation 49 CFR
391.41(b)(4). A summary of each
applicant’s medical history related to
their ICD exemption request was
discussed in the May 4, 2017, Federal
Register notice and will not be repeated
in this notice.
In reaching the decision to deny these
exemption requests, the Agency
considered information from the
Cardiovascular Medical Advisory
Criteria, the April 2007 Evidence Report
‘‘Cardiovascular Disease and
Commercial Motor Vehicle Driver
Safety, a December 2014 focused
research report ‘‘Implantable
Cardioverter Defibrillators and the
Impact of a Shock in a Patient When
Deployed.’’ Copies of the reports are
included in the docket.
FMCSA has published advisory
criteria to assist medical examiners in
determining whether drivers with
certain medical conditions are qualified
to operate a CMV in interstate
commerce. [Appendix A to Part 391—
Medical Advisory Criteria, section D,
paragraph 4.] The advisory criteria for
49 CFR 391.41(b)(4) indicates that
coronary artery bypass surgery and
pacemaker implantation are remedial
procedures and thus, not medically
disqualifying. Implantable cardioverter
defibrillators are disqualifying due to
risk of syncope.
III. Discussion of Comments
FMCSA received two comments in
this proceeding. Each of the comments
was favorable towards the applicants
continuing to drive CMV’s with ICD’s
citing their ICDs have not deployed and
their medical and physical conditions
are stable. FMCSA acknowledges the
commenters’ responses concerning
stable medical histories with ICDs.
Based on the available medical
literature cited above, however, FMCSA
believes that a driver with an ICD is at
risk for incapacitation if the device
discharges. This risk is combined with
the risks associated with the underlying
cardiovascular condition for which the
E:\FR\FM\16JAN1.SGM
16JAN1
2292
Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices
ICD has been implanted as a primary or
secondary preventive measure.
the Agency’s recent denials as required
under 49 U.S.C. 31315(b)(4).
IV. Basis for Exemption Determination
Issued on: January 5, 2018.
Larry W. Minor,
Associate Administrator for Policy.
Under 49 U.S.C.31136(e) and 31315,
FMCSA may grant an exemption if it
finds such an exemption would likely
achieve a level of safety that is
equivalent to, or greater then, the level
that would be achieved absent such an
exemption.
The Agency’s decision regarding these
exemption applications is based on an
individualized assessment of each
applicant’s medical information
provided by the applicant, available
medical and scientific data concerning
ICDs, and public comments received.
In the case of persons with ICDs, the
underlying condition for which the ICD
was implanted places the individual at
high risk for syncope (a transient loss of
consciousness) or other unpredictable
events known to result in gradual or
sudden incapacitation. ICDs may
discharge, which could result in loss of
ability to safely control a CMV. See the
April 2007 Evidence Report on
Cardiovascular Disease and Commercial
Motor vehicle Driver Safety, April
2007.1 A focused research report on
Implantable Cardioverter Defibrillators
and the Impact of a Shock on a Patient
When Deployed completed for the
FMCSA December 2014 indicates that
the available scientific data on persons
with ICDs and CMV driving does not
support that persons with ICDs who
operate CMVs are able to meet an equal
or greater level of safety and upholds
the findings of the April 2007 report.
V. Conclusion
The Agency has determined that the
available medical and scientific
literature and research provides
insufficient data to enable the Agency to
conclude that granting these exemptions
would achieve a level of safety
equivalent to, or greater than, the level
of safety maintained without the
exemption. Therefore, the following two
applicants have been denied
exemptions from the physical
qualification standards in 49 CFR
391.41(b)(4):
daltland on DSKBBV9HB2PROD with NOTICES
Justin D. Dale (IA)
Raymond M. Loffredo (PA)
Each applicant has, prior to this
notice, received a letter of final
disposition regarding his/her exemption
request. Those decision letters fully
outlined the basis for the denial and
constitutes final action by the Agency.
The list published today summarizes
1 Now available at https://ntl.bts.gov/lib/30000/
30100/30123/Final_CVD_Evidence_Report_v2.pdf.
VerDate Sep<11>2014
22:48 Jan 12, 2018
Jkt 244001
[FR Doc. 2018–00560 Filed 1–12–18; 8:45 am]
BILLING CODE 4910–EX–P
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety
Administration
[Docket No. FMCSA–2017–0027]
Qualification of Drivers; Exemption
Applications; Vision
Federal Motor Carrier Safety
Administration (FMCSA), DOT.
ACTION: Notice of applications for
exemption; request for comments.
AGENCY:
FMCSA announces receipt of
applications from 14 individuals for an
exemption from the vision requirement
in the Federal Motor Carrier Safety
Regulations (FMCSRs) to operate a
commercial motor vehicle (CMV) in
interstate commerce. If granted, the
exemptions will enable these
individuals to operate CMVs in
interstate commerce without meeting
the vision requirement in one eye.
DATES: Comments must be received on
or before February 15, 2018.
ADDRESSES: You may submit comments
bearing the Federal Docket Management
System (FDMS) Docket No. FMCSA–
2017–0027 using any of the following
methods:
• Federal eRulemaking Portal: Go to
https://www.regulations.gov. Follow the
online instructions for submitting
comments.
• Mail: Docket Management Facility;
U.S. Department of Transportation, 1200
New Jersey Avenue SE, West Building
Ground Floor, Room W12–140,
Washington, DC 20590–0001.
• Hand Delivery: West Building
Ground Floor, Room W12–140, 1200
New Jersey Avenue SE, Washington,
DC, between 9 a.m. and 5 p.m., ET,
Monday through Friday, except Federal
Holidays.
• Fax: 1–202–493–2251.
Instructions: Each submission must
include the Agency name and the
docket number(s) for this notice. Note
that all comments received will be
posted without change to https://
www.regulations.gov, including any
personal information provided. Please
see the Privacy Act heading below for
further information.
Docket: For access to the docket to
read background documents or
SUMMARY:
PO 00000
Frm 00162
Fmt 4703
Sfmt 4703
comments, go to https://
www.regulations.gov at any time or
Room W12–140 on the ground level of
the West Building, 1200 New Jersey
Avenue SE, Washington, DC, between 9
a.m. and 5 p.m., ET, Monday through
Friday, except Federal holidays. The
FDMS is available 24 hours each day,
365 days each year. If you want
acknowledgment that we received your
comments, please include a selfaddressed, stamped envelope or
postcard or print the acknowledgement
page that appears after submitting
comments online.
Privacy Act: In accordance with 5
U.S.C. 553(c), DOT solicits comments
from the public to better inform its
rulemaking process. DOT posts these
comments, without edit, including any
personal information the commenter
provides, to https://www.regulations.gov,
as described in the system of records
notice (DOT/ALL–14 FDMS), which can
be reviewed at https://www.dot.gov/
privacy.
Ms.
Christine A. Hydock, Chief, Medical
Programs Division, (202) 366–4001,
fmcsamedical@dot.gov, FMCSA,
Department of Transportation, 1200
New Jersey Avenue SE, Room W64–224,
Washington, DC 20590–0001. Office
hours are 8:30 a.m. to 5 p.m., ET,
Monday through Friday, except Federal
holidays. If you have questions
regarding viewing or submitting
material to the docket, contact Docket
Services, telephone (202) 366–9826.
SUPPLEMENTARY INFORMATION:
FOR FURTHER INFORMATION CONTACT:
I. Background
Under 49 U.S.C. 31136(e) and 31315,
FMCSA may grant an exemption from
the FMCSRs for a five-year period if it
finds ‘‘such exemption would likely
achieve a level of safety that is
equivalent to or greater than the level
that would be achieved absent such
exemption.’’ The statute also allows the
Agency to renew exemptions at the end
of the five-year period. FMCSA grants
exemptions from the FMCSRs for a twoyear period to align with the maximum
duration of a driver’s medical
certification.
The 14 individuals listed in this
notice have requested an exemption
from the vision requirement in 49 CFR
391.41(b)(10). Accordingly, the Agency
will evaluate the qualifications of each
applicant to determine whether granting
an exemption will achieve the required
level of safety mandated by statute.
The physical qualification standard
for drivers regarding vision found in 49
CFR 391.41(b)(10) states that a person is
physically qualified to drive a CMV if
E:\FR\FM\16JAN1.SGM
16JAN1
Agencies
[Federal Register Volume 83, Number 10 (Tuesday, January 16, 2018)]
[Notices]
[Pages 2291-2292]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-00560]
-----------------------------------------------------------------------
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration
[Docket No. FMCSA-2017-0116]
Qualification of Drivers; Exemption Applications; Implantable
Cardioverter Defibrillator (ICD)
AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.
ACTION: Notice of denials.
-----------------------------------------------------------------------
SUMMARY: FMCSA announces its decision to deny applications from two
individuals treated with Implantable Cardioverter Defibrillators (ICDs)
who requested an exemption from the Federal Motor Carrier Safety
Regulations (FMCSRs) prohibiting operation of a commercial motor
vehicle (CMV) in interstate commerce by persons with a current clinical
diagnosis of myocardial infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other cardiovascular disease of a
variety known to be accompanied by syncope, dyspnea, collapse, or
congestive heart failure.
FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief,
Medical Programs Division, (202) 366-4001, [email protected], FMCSA,
Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224,
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m.,
ET, Monday through Friday, except Federal holidays. If you have
questions regarding viewing or submitting material to the docket,
contact Docket Services, telephone (202) 366-9826.
SUPPLEMENTARY INFORMATION:
I. Electronic Access
You may see all the comments online through the Federal Document
Management System (FDMS) at: https://www.regulations.gov.
Docket: For access to the docket to read background documents or
comments, go to https://www.regulations.gov and/or Room W12-140 on the
ground level of the West Building, 1200 New Jersey Avenue SE,
Washington, DC, between 9 a.m. and 5 p.m., ET, Monday through Friday,
except Federal holidays.
Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to https://www.regulations.gov, as described in
the system of records notice (DOT/ALL-14 FDMS), which can be reviewed
at https://www.dot.gov/privacy.
II. Background
On May 4, 2017, FMCSA published a FR notice (82 FR 20961)
announcing receipt of applications from two individuals treated with
ICDs and requested comments from the public. These two individuals
requested an exemption from 49 CFR 391.41(b)(4) which prohibits
operation of a CMV in interstate commerce by persons with a current
clinical diagnosis of myocardial infarction, angina pectoris, coronary
insufficiency, thrombosis, or any other cardiovascular disease of a
variety known to be accompanied by syncope, dyspnea, collapse, or
congestive heart failure. The public comment period closed on June 5,
2017, and two comments were received.
FMCSA has evaluated the eligibility of these applicants and
concluded that granting these exemptions would not provide a level of
safety that would be equivalent to or greater than, the level of safety
that would be obtained by complying with the regulation 49 CFR
391.41(b)(4). A summary of each applicant's medical history related to
their ICD exemption request was discussed in the May 4, 2017, Federal
Register notice and will not be repeated in this notice.
In reaching the decision to deny these exemption requests, the
Agency considered information from the Cardiovascular Medical Advisory
Criteria, the April 2007 Evidence Report ``Cardiovascular Disease and
Commercial Motor Vehicle Driver Safety, a December 2014 focused
research report ``Implantable Cardioverter Defibrillators and the
Impact of a Shock in a Patient When Deployed.'' Copies of the reports
are included in the docket.
FMCSA has published advisory criteria to assist medical examiners
in determining whether drivers with certain medical conditions are
qualified to operate a CMV in interstate commerce. [Appendix A to Part
391--Medical Advisory Criteria, section D, paragraph 4.] The advisory
criteria for 49 CFR 391.41(b)(4) indicates that coronary artery bypass
surgery and pacemaker implantation are remedial procedures and thus,
not medically disqualifying. Implantable cardioverter defibrillators
are disqualifying due to risk of syncope.
III. Discussion of Comments
FMCSA received two comments in this proceeding. Each of the
comments was favorable towards the applicants continuing to drive CMV's
with ICD's citing their ICDs have not deployed and their medical and
physical conditions are stable. FMCSA acknowledges the commenters'
responses concerning stable medical histories with ICDs. Based on the
available medical literature cited above, however, FMCSA believes that
a driver with an ICD is at risk for incapacitation if the device
discharges. This risk is combined with the risks associated with the
underlying cardiovascular condition for which the
[[Page 2292]]
ICD has been implanted as a primary or secondary preventive measure.
IV. Basis for Exemption Determination
Under 49 U.S.C.31136(e) and 31315, FMCSA may grant an exemption if
it finds such an exemption would likely achieve a level of safety that
is equivalent to, or greater then, the level that would be achieved
absent such an exemption.
The Agency's decision regarding these exemption applications is
based on an individualized assessment of each applicant's medical
information provided by the applicant, available medical and scientific
data concerning ICDs, and public comments received.
In the case of persons with ICDs, the underlying condition for
which the ICD was implanted places the individual at high risk for
syncope (a transient loss of consciousness) or other unpredictable
events known to result in gradual or sudden incapacitation. ICDs may
discharge, which could result in loss of ability to safely control a
CMV. See the April 2007 Evidence Report on Cardiovascular Disease and
Commercial Motor vehicle Driver Safety, April 2007.\1\ A focused
research report on Implantable Cardioverter Defibrillators and the
Impact of a Shock on a Patient When Deployed completed for the FMCSA
December 2014 indicates that the available scientific data on persons
with ICDs and CMV driving does not support that persons with ICDs who
operate CMVs are able to meet an equal or greater level of safety and
upholds the findings of the April 2007 report.
---------------------------------------------------------------------------
\1\ Now available at https://ntl.bts.gov/lib/30000/30100/30123/Final_CVD_Evidence_Report_v2.pdf.
---------------------------------------------------------------------------
V. Conclusion
The Agency has determined that the available medical and scientific
literature and research provides insufficient data to enable the Agency
to conclude that granting these exemptions would achieve a level of
safety equivalent to, or greater than, the level of safety maintained
without the exemption. Therefore, the following two applicants have
been denied exemptions from the physical qualification standards in 49
CFR 391.41(b)(4):
Justin D. Dale (IA)
Raymond M. Loffredo (PA)
Each applicant has, prior to this notice, received a letter of
final disposition regarding his/her exemption request. Those decision
letters fully outlined the basis for the denial and constitutes final
action by the Agency. The list published today summarizes the Agency's
recent denials as required under 49 U.S.C. 31315(b)(4).
Issued on: January 5, 2018.
Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2018-00560 Filed 1-12-18; 8:45 am]
BILLING CODE 4910-EX-P